Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Contact Inhibition

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    131 result(s) found for: Contact Inhibition. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2016-003830-26 Sponsor Protocol Number: LPRI-421/201 Start Date*: 2017-02-24
    Sponsor Name:Exeltis France
    Full Title: Single center, phase II, open label randomized clinical trial to evaluate the inhibition of ovulation of three prolonged release formulations containing a combination of Dienogest and Ethinyl Estra...
    Medical condition: Women’s healthcare (contraception, inhibition of ovulation).
    Disease: Version SOC Term Classification Code Term Level
    19.1 10042613 - Surgical and medical procedures 10010808 Contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-005015-29 Sponsor Protocol Number: GS101-P2-CG Start Date*: 2005-08-03
    Sponsor Name:Les Laboratoires CTRS
    Full Title: A multicenter double-blind randomized study to investigate the efficacy and tolerability of three doses of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal ne...
    Medical condition: Patients suffering from keratitis or keratouveitits of infectious origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004612-23 Sponsor Protocol Number: TV-3326/201 Start Date*: 2005-04-13
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: A multi-center, randomized, double-blind, placebo-controlled, sequential cohort designed, escalating dose study to assess the tolerability, safety and maximal tolerated dose (MTD) of Ladostigil in ...
    Medical condition: Patients with probable Alzheimer's Disease (AD) diagnosis according to NINCDS-ADRDA and DSM–IV criteria, who suffer from mild to moderate dementia with a Mini Mental State Examination (MMSE) of 15-26
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001897 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013837-92 Sponsor Protocol Number: 113459 Start Date*: 2010-09-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, randomized, trial to evaluate the immunogenicity and safety of a single or two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adj...
    Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 years and above.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016078-33 Sponsor Protocol Number: 113866 Start Date*: 2009-10-06
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, observer-blind, randomised trial to evaluate the safety and immunogenicity of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adju...
    Medical condition: Immunisation against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 to 60 years.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015008-25 Sponsor Protocol Number: 113630 Start Date*: 2009-09-08
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, non-randomized, trial to evaluate the immunogenicity and safety of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvante...
    Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 years and above.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004043-36 Sponsor Protocol Number: 004:TCELL Start Date*: 2017-04-28
    Sponsor Name:Uppsala University
    Full Title: CD19-TARGETING 3RD GENERATION CAR T CELLS FOR REFRACTORY B CELL MALIGNANCY – A PHASE II TRIAL
    Medical condition: CD19+ B cell lymphoma or leukemia
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020181-21 Sponsor Protocol Number: BAY86-5028/13362 Start Date*: 2011-01-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter, randomized, open-label, parallel-group study to evaluate user satisfaction with and tolerability of the low-dose levonorgestrel (LNG) intrauterine delivery system (IUS) with 12 µg LNG/...
    Medical condition: The aim of the present study is to examine the overall satisfaction with and tolerability of LCS12 compared with a standard combined oral contraceptive (COC; Yasmin; 30 µg ethinyl estradiol and 3 m...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10010808 Contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015902-20 Sponsor Protocol Number: GHB-CS07 Start Date*: 2009-11-04
    Sponsor Name:AVIR Green Hills Biotechnology Research Development Trade AG
    Full Title: Randomized, double-blind, placebo-controlled, Phase IIa dose finding study of single dose GHB11L1 in healthy adults
    Medical condition: GHB-CS07 is a healthy volunteer trial. The intended indication for the investigational medicinal product (GHB11L1) is prevention of influenza A (H1N1).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001042-24 Sponsor Protocol Number: INFQ3001 Start Date*: 2015-05-27
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: Randomized, Double-Blind, Active-Controlled Study in Adults to Assess the Safety and Immunogenicity of Abbott’s Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority to Trivalent Influen...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10022005 Influenza viral infections HLT
    18.1 10022891 - Investigations 10062297 Immunology test PT
    18.1 10018065 - General disorders and administration site conditions 10065109 Reactogenicity event PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) HU (Completed) LT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004187-30 Sponsor Protocol Number: CO17730 Start Date*: 2011-12-14
    Sponsor Name:Avraham Pharmaceuticals Ltd.
    Full Title: A 36-month, multi-centre, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of low dose Ladostigil in patients with Mild Cognitive Impairment (MCI)
    Medical condition: Patient with Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005482-23 Sponsor Protocol Number: INFQ3002 Start Date*: 2016-07-28
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: Randomized, Double-Blind and Active-Controlled Study in Children and Adolescents Aged 3–17 Years to Assess the Safety and Immunogenicity of Abbott’s Candidate Quadrivalent Influenza Vaccine and its...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) EE (Completed) HU (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002887-42 Sponsor Protocol Number: EORTC-1612-MG Start Date*: 2018-06-28
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresect...
    Medical condition: BRAF V600 mutation–positive unresectable or metastatic melanoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) PL (Ongoing) NL (Ongoing) DK (Completed) ES (Ongoing) IT (Ongoing) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003980-74 Sponsor Protocol Number: BAY1007626/15731 Start Date*: 2015-06-17
    Sponsor Name:Bayer AG
    Full Title: Multi-center, randomized, comparator-controlled, single-blind, parallel-group study to investigate the pharmacodynamics, pharmacokinetics and safety of an intrauterine system releasing BAY 1007626,...
    Medical condition: Contraception
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10010809 Contraception NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000022-66 Sponsor Protocol Number: 16-HMedIdeS-12 Start Date*: 2019-03-13
    Sponsor Name:Hansa Medical AB
    Full Title: A Randomized, Open-Label, Multi-Centre, Active Control Study Investigating the Efficacy and Safety of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibod...
    Medical condition: Antibody-mediated rejection in kidney transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002101-21 Sponsor Protocol Number: ARGX-113-1803 Start Date*: 2020-05-25
    Sponsor Name:argenx BV
    Full Title: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia
    Medical condition: Primary immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Ongoing) HU (Trial now transitioned) FR (Completed) BE (Completed) CZ (Ongoing) BG (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003298-10 Sponsor Protocol Number: C0524T08 Start Date*: 2006-06-07
    Sponsor Name:Centocor BV
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Psoriatic Arthritis
    Medical condition: Psoriatic Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002419-32 Sponsor Protocol Number: 2017-40 Start Date*: 2017-08-29
    Sponsor Name:Research Maatschap Cardiologen Rijnmond Zuid
    Full Title: COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions’
    Medical condition: ST elevated Myocardial infarction (STEMI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064346 STEMI LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002065-37 Sponsor Protocol Number: BAY86-5028 / 14371 Start Date*: 2011-09-12
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multi-center, single-arm study to assess the safety, efficacy, discontinuation rate and pharmacokinetics of the low-dose levonorgestrel intrauterine contraceptive system (LCS12) in post-menarcheal ...
    Medical condition: Contraception
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10010808 Contraception PT
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: SE (Completed) FI (Completed) NL (Completed) AT (Completed) BE (Completed) DE (Completed) DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2011-003168-63 Sponsor Protocol Number: AMLSG16-10/CPKC412ADE02T Start Date*: 2012-04-27
    Sponsor Name:University Hospital Ulm
    Full Title: Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leuk...
    Medical condition: Patients with confirmed diagnosis of AML or related precursor neoplasm, or acute leukemia of ambiguous lineage (classified according to the World Health Organization (WHO) 2008 classification)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:30:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA